Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human matrix metalloproteinase
- Development stage
- Phase 2
- Lead developer
- Teijin Pharma
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intradiscal
01
Overview
KTP-001 is a recombinant human matrix metalloproteinase (MMP) developed primarily by Teijin Pharma and KM Biologics for the treatment of intervertebral disc displacement. It acts as a stimulant of matrix metalloproteinases, enzymes involved in the breakdown and remodeling of extracellular matrix components. The drug is classified as a new molecular entity and falls under the class of recombinant proteins. Its primary therapeutic area is skin and musculoskeletal diseases, with clinical development focused on lumbar disc herniation/intervertebral disc displacement[1][2]. Clinical trials have reached up to Phase 2; however, development for intervertebral disc displacement has been discontinued[2].
- Other names
- recombinant human matrix metalloproteinase
02
Targets
Tissue inhibitor of metalloproteinases 2–Matrix metalloproteinase 2 protein–protein interfaceMMP12 (Macrophage Metalloelastase)
Beyond the preview
Go deeper on recombinant human matrix metalloproteinase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human matrix metalloproteinase.